SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Patel, P S
Right arrow Articles by Rifkin, I R
Right arrow Search for Related Content
PubMed
Right arrow Articles by Patel, P S
Right arrow Articles by Rifkin, I R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Mycophenolate and nephrology

P S Patel

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

I R Rifkin

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA, irifkin{at}bu.edu

Several large, randomized trials have established mycophenolate mofetil (MMF) as an effective immunosuppressant for kidney transplantation. Inhibition of inosine 5 -monophospate dehydrogenase (IMPDH) by MMF appears to have pleiotropic effects on both immune and non-immune cells. In addition to B- and T-cell inhibition, in vitro and in vivo data suggest that MMF also has inhibitory effects on smooth muscle cells, endothelial cells, and myofibroblasts, findings that may be relevant in considering treatment of primary immune mediated kidney diseases. Clinical trials have established the efficacy of MMF for the treatment of lupus nephritis, as discussed in detail elsewhere in this supplement. Although animal studies have provided the rationale for human trials of MMF in primary glomerular diseases, most of the evidence thus far is conflicting or based largely on pilot studies. Data from larger, controlled trials will soon emerge and may clarify the role of MMF in the treatment of these disorders.

Key Words: glomerulonephritis • IgA nephropathy • mycophenolate • transplantation

Lupus, Vol. 15, No. 11 suppl, 39-43 (2006)
DOI: 10.1177/0961203306071666
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement